Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) concentrations are inversely correlated and mechanistically linked by means of lipid transfer activities. Phospholipid transfer activity (PLTA) moves phospholipids among serum lipoproteins; cholesteryl ester transfer activity (CETA), which exchanges cholesteryl esters (CE) and TG among lipoproteins, is stimulated by nonesterified fatty acids (NEFA). The aims of this study were (a) to develop a quantitative model that correlates the neutral lipid (NL = CE + TG) compositions of HDL and LDL with serum TG concentration; (b) identify the serum lipid determinants of CETA and PLTA, and; (c) identify the effects of serum TG reductions on the neutral lipid compositions of HDL and LDL, serum NEFA concentrations, and on PLTA and CETA. These aims were addressed in 40 hypertriglyceridemic subjects before and after treatment with an 85% concentrate of omega-3 fatty acids (Omacor) and in 16 untreated normolipidemic subjects. In vivo, the NL compositions of LDL and HDL were described by a mathematical model having the form of adsorption isotherms: HDL - (TG/NL) = (0.90 +/- 0.07) serum TG/(7.0 +/- 1.2 mmol/l + serum TG) and LDL - (TG/NL) = (0.65 +/- 0.08) serum TG/(4.9 +/- 1.5 mmol/l + serum TG). Reduction of serum TG was associated with reductions in HDL - (TG/NL), serum NEFA concentration, and serum CETA but not PLTA. These data suggest that both hypertriglyceridemia and the attendant elevated serum CETA but not PLTA a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plasma triglyceride levels were reduced by 30% to 35% in individuals with baseline triglycerides of 600 to 800 mg/dL.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [21]
In the citing paper
“In patients with VHTG (triglycerides, 500-2000 mg/dL), treatment with IPE did not raise LDL-C, and apo B decreased, suggesting differing effects from those of EPA+DHA.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [21]
In the citing paper
“In a subanalysis of the IPE study, the placebo-corrected triglyceride-lowering effect in patients with triglycerides >750 mg/dL (mean, ≈900 mg/dL) was 45% (control, 19%; active, -27%).”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [21]
In the citing paper
“All 3 FDA-approved agents, O3AEE, 19,20 IPE, 21 and O3CA, 22 have been tested at 4 g/d in affected patients.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [21]
In the citing paper
“In treatment of very high triglycerides with 4 g/d, EPA+DHA agents reduce triglycerides by ≥30% with concurrent increases in low-density lipoprotein cholesterol, whereas EPA-only did not raise low-density lipoprotein cholesterol in very high triglycerides.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [21]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Molecular physiology of reverse cholesterol transport.
Fielding, C. J., & Fielding, P. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39898-9 · Cited by 1,448
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 2×
“Hypertriglyceridemia is associated with derangements in other serum lipid and lipoprotein analytes, including decreased concentrations of high-density lipoprotein cholesterol (HDL-C) [1] and the occurrence of small, dense low-density lipoproteins (LDL) [2,3].”
BackgroundCardiovascular Effects of n-3 Fatty Acids
Leaf, A., & Weber, P. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198803033180905 · Cited by 1,169 · cited 1×
“disease events [40–43].”
Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review
Harris, W. S. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38310-3 · Cited by 1,127
Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957 · cited 1×
“As observed with other hypotriglyceridemic interventions, such as nicotinic acid, and fibric-acid derivatives [51–54], and other fish oil products [24], v-3 fatty acids increased not only HDL-C but also LDL-C (Table 3).”
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 710
Research works printed but not linked: 4
- Tu, 1993, High density lipoprotein conversion mediated by human serum phospholipid transfer protein, J. Biol. Chem., 268, 23098, 10.1016/s0021-9258(19)49431-3 · DOI · Paper page
- International Task Force. Prevention of coronary heart disease: scientific background and new clinical guidelines: recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992;2:113–156.
- Weintraub, 1988, Dietary polyunsaturated fats of the ω-6 and ω-3 series reduce postprandial lipoprotein levels, J. Clin. Invest., 82, 1884, 10.1172/jci113806 · DOI · Paper page
- Shepherd, 1991, The action of nicotinic acid and its analogues on lipoprotein metabolism, Atheroscler. Rev., 22, 207
Cited by
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives
Harris, W. S., Miller, M., Tighe, A. P., Davidson, M. H., & Schaefer, E. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.008 · Cited by 552
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Self-citation
Metadata
- Authors
- Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M.
- Affiliations
- Houston Methodist (US)
- Corresponding author
- Pownall, Henry J
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 143
- Issue
- 2
- Pages
- 285-297
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2052264489
- Cited by
- 179
- References
- 64
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 4 · 2018: 2 · 2017: 8 · 2016: 13 · 2015: 13 · 2014: 8 · 2013: 17 · 2012: 8
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-30914, R01HL056865, R01HL030914, HL56865)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- serum triglycerides, omega-3 fatty acids, HDL cholesterol, LDL cholesterol, neutral lipids, cholesterol esters, free fatty acids, hypertriglyceridemia, adsorption isotherm models, triglyceride lowering, Omacor
- MeSH terms
- Adolescent, Adult, Aged, Biological Transport, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type IV, Lipoproteins, HDL, Lipoproteins, LDL, Male, Middle Aged, Reference Values, Software, Triglycerides, Fatty Acids, Omega-3, Treatment Outcome, Statistics, Nonparametric
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. https://app.cochat.ai/papers/10.1016/s0021-9150(98)00301-3
- The paper
- Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999). Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. https://doi.org/10.1016/s0021-9150(98)00301-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.